CT-996
About
About CT-996
CT-996 is Structure Therapeutics' oral small-molecule GLP-1 receptor agonist in early clinical development, designed for once-daily oral dosing with minimal food restrictions. Phase Ib data showed up to 6% weight loss over 28 days, promising for an early-stage program. It competes in the oral GLP-1 space with orforglipron and danuglipron, differentiated by its distinct chemical scaffold and once-daily convenience.
Science
Mechanism of Action
Non-peptide small molecule GLP-1 receptor agonist acting on both central (hypothalamic appetite regulation) and peripheral (pancreatic insulin secretion, gastric motility) GLP-1 receptor populations through oral bioavailable formulation.
Dosing
Typical Protocol
Oral once-daily dosing; Phase Ib doses and titration schedule under clinical investigation.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Regulatory
Legal Status in 2026
This compound occupies a regulatory grey area in 2026. It is neither explicitly FDA-approved nor clearly illegal for personal use, but it lacks formal clinical approval and may not be legally sold for human use in all contexts. Proceed with caution: source quality is variable, and regulatory status can change. Always consult a physician.
Evidence
Evidence Tier
Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.
Find a Verified Provider
See which Vial-verified providers offer CT-996 — with trust scores, legal credentials, and pricing transparency.